Press releases
- ViiV Healthcare presents positive new findings from two studies of its investigational, long-acting regimen of cabotegravir and rilpivirine, including five-year data showing long-term durability, efficacy, safety, and tolerability
- ViiV Healthcare presents continued positive findings from first-ever implementation science study on integrating an investigational once-monthly injectable HIV treatment into US healthcare practices
- ViiV Healthcare announces analysis showing no antiretroviral therapy interruptions due to COVID-19 across its clinical development programme for investigational, long-acting cabotegravir and rilpivirine
Tweets from GSK US
-
GSKUS @GSKUS
We’re supporting the voice of the patient by working together to eliminate access barriers at the Alliance for Health Policy, Voice of the Patient Health Summit 2020. #AHPSummit20 #patientvoice twitter.com/AllHealthPolic…
about 21 hours ago
-
GSKUS @GSKUS
The @HBCUCaucus and @RepAdams are virtually hosting #HBCUDay to highlight and celebrate #HBCU culture. We're tuning in today to learn more about what makes HBCUs great! Click below to learn more about our open roles and opportunities at GSK. #HBCUStrong
about 3 days ago -
GSKUS @GSKUS
DYK #severeasthma impacts up to 10% of all people living with the disease and has a distinct cause? Learn more about how #eosinophils, a type of white blood cell, can impact #asthma symptoms and how a personalized approach to treatment may help.
about 6 days ago
